Veru Enrolls First Patient in Phase 2b PLATEAU Trial of Enobosarm Plus Semaglutide
Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial evaluating enobosarm combined with semaglutide for weight loss in older patients with obesity. The study will assess enobosarm's ability to preserve lean mass and physical function while augmenting fat loss.